You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, November 2019
|
| DOI | 10.1186/s40425-019-0793-8 |
| Pubmed ID | |
| Authors |
Lorenza Landi, Federica D’Incà, Alain Gelibter, Rita Chiari, Francesco Grossi, Angelo Delmonte, Antonio Passaro, Diego Signorelli, Francesco Gelsomino, Domenico Galetta, Diana Giannarelli, Hector Soto Parra, Gabriele Minuti, Marcello Tiseo, Maria Rita Migliorino, Francesco Cognetti, Luca Toschi, Paolo Bidoli, Francovito Piantedosi, Luana Calabro’, Federico Cappuzzo |
| Abstract |
Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM. Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, p < 0.0001; Cohort B: 13% versus 22%, p = 0.04), shorter progression free survival (PFS; Cohort A: 3.0 versus 4.0 months, p < 0.0001; Cohort B: 2.7 versus 5.2 months, p < 0.0001) and overall survival (OS; Cohort A: 7.4 versus 15.3 months, p < 0.0001; Cohort B: 5.0 versus 10.9 months, p < 0.0001). Moreover, BoM negatively affected outcome irrespective of performance status (PS; OS in both cohorts: p < 0.0001) and liver metastases (OS cohort A: p < 0.0001; OS Cohort B: p = 0.48). At multivariate analysis, BoM independently associated with higher risk of death (cohort A: HR 1.50; cohort B: HR 1.78). BoM impairs immunotherapy efficacy. Accurate bone staging should be included in clinical trials with immunotherapy. |
X Demographics
The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 18% |
| Japan | 2 | 12% |
| India | 1 | 6% |
| Germany | 1 | 6% |
| Ireland | 1 | 6% |
| Russia | 1 | 6% |
| Switzerland | 1 | 6% |
| Italy | 1 | 6% |
| Unknown | 6 | 35% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 53% |
| Practitioners (doctors, other healthcare professionals) | 5 | 29% |
| Science communicators (journalists, bloggers, editors) | 2 | 12% |
| Scientists | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 65 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 22% |
| Student > Master | 7 | 11% |
| Student > Bachelor | 6 | 9% |
| Other | 4 | 6% |
| Student > Doctoral Student | 3 | 5% |
| Other | 10 | 15% |
| Unknown | 21 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 28% |
| Biochemistry, Genetics and Molecular Biology | 10 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Engineering | 2 | 3% |
| Mathematics | 1 | 2% |
| Other | 5 | 8% |
| Unknown | 26 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2019.
All research outputs
#3,837,314
of 25,604,262 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,058
of 3,470 outputs
Outputs of similar age
#88,358
of 476,626 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#36
of 98 outputs
Altmetric has tracked 25,604,262 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,470 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 476,626 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.